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EPA and DHA are required for normal cell function and can also induce health benefits.  Oily fish 
are the main source of EPA and DHA for human consumption.  However, food choices and 
concerns about the sustainability of marine fish stocks limit the effectiveness of dietary 
recommendations for EPA+DHA intakes.  Seed oils from transgenic plants that contain EPA+DHA 
are a potential alternative source of EPA and DHA.  The present study investigated whether dietary 
supplementation with transgenic Camelina sativa seed oil (CSO) that contained EPA and DHA was 
as effective as fish oil (FO) in increasing EPA and DHA concentrations when consumed as a 
dietary supplement in a blinded crossover study.  Healthy men and women (n 31; age 53 (20-74) 
yrs) were randomised to consume 450 mg/day EPA+DHA provided either as either CSO or FO for 
8 weeks, followed by 6 weeks washout and then switched to consuming the other test oil.  Fasting 
venous blood samples were collected at the start and end of each supplementation period.  
Consuming the test oils significantly (P < 0.05) increased EPA and DHA concentrations in plasma 
triacylglycerol, phosphatidylcholine and cholesteryl esters.  There were no significant differences 
between test oils in the increments of EPA and DHA. There was no significant difference between 
test oils in the increase in the proportion of erythrocyte EPA+DHA (CSO, 12%; P < 0.0001 and FO, 
8%; P = 0.02).  Together these findings show that consuming CSO is as effective as FO for 
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n-3 polyunsaturated fatty acids (PUFA), namely eicosapentaenoic acid (EPA, 20:5n-3) and 
docosahexaenoic acid (DHA, 22:6n-3), are present primarily in oily fish and are important for 
development and tissue function.  DHA is important for the development and function of the central 
nervous system, including the retina
(1; 2)
.  EPA is a substrate for the synthesis of a range 
immunomodulatory second messengers
(3)
.  Increased EPA+DHA intake can convey health benefits 
such as reduced inflammation, and lower postprandial and fasting blood triacylglycerol (TG) 
concentration
(4)
.  Moreover, the sum of the proportions of EPA+DHA in erythrocytes, the omega-3 
index, is a biomarker of cardiovascular disease risk
(5)
.  
 Although humans are able to synthesise some EPA and DHA from the essential fatty acid α-
linolenic acid (ALA, 18:3n-3) found vegetable oils, the activity of this pathway is low and its 
contribution to meeting demands is not known
(6)
.  Consequently, humans rely primarily on 
consumption of pre-formed EPA and DHA in their diet.  Some governments and advisory 
organisations have published guidelines and recommendations for EPA and DHA intake.  For 
example, the UK government recommends that all adults consume 450 mg EPA+DHA / day to 
maintain health
(7)
.  However, the effectiveness of such recommendations is constrained by dietary 
choices of the population.  For example, only about 27% of UK fish consumers eat oily fish and 
overall UK adults consume less than 200 mg EPA+DHA/day, while children consume 
approximately one tenth of the adult intake
(8; 9)
.  Such avoidance of oily fish reflects, at least in part, 
the cost of oily fish, perceived unpalatability, and concerns about contamination with environmental 
pollutants
(8; 9)
.  Vegetarians and vegans who exclude fish and meat, or fish, meat and dairy products 
from their diet have approximately 50% lower EPA and DHA levels in blood compared to 
omnivores
(10)
.  In addition to the limited compliance to recommendations for EPA+DHA by the UK 
population, consumption of oily fish and, in particular, the production of fish oils (FO) represents a 
substantial demand on marine ecosystems.  Even at present levels, the total marine production of 
EPA and DHA from oily fish has been estimated to be approximately 1.1 million metric tonnes less 
than that required to meet the needs to the global population for EPA and DHA
(11)
.  Hence, there is 
a need for alternative sustainable, affordable, and scalable sources of EPA and DHA that are 
compatible with the full range of human dietary choices.      
   Alternative sources of EPA and DHA to oily fish include krill which produces a yield of 
EPA+DHA equivalent to 0.3% of the global production of these fatty acids and algal oils which 
account for less than 2% global EPA+DHA production
(11)
.  Increasing production of EPA+DHA 
from krill has raised concerns about possible negative  impact on the ecology of the South 
Atlantic
(11)
.  The cost of increasing the scale of EPA+DHA production from algae is likely to be 
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but with an EPA content below 1%
(12)
.  Vegetable oils that the contain ALA are unlikely to be an 
effective means of meeting the demands for EPA and DHA in humans because of low capacity for 
ALA interconversion
(6)
.    
 Genetic modification of oil seed plants is potentially a sustainable means of producing EPA 
and DHA for human consumption that is consistent with dietary choices that exclude animal-
derived foods and doesn’t incur concerns about environmental contaminants or palatability.   
Strains of transgenic Camelina sativa and canola have been developed that produce seeds oils 
which contain EPA and DHA
(12)
, of which one strain of transgenic C. sativa produced a seed oil 
that approximated the EPA and DHA content of marine FO
(13)
.  To date, the acute bioavailability of 
EPA and DHA in humans when consumed as the seed oil from a transgenic plant has only been 
tested for this one transgenic C. sativa strain.  The findings showed that there was no significant 
differences in men and women aged 18  - 30 years or 50 – 65 years in the postprandial 
incorporation of EPA and DHA into blood lipids between FO and transgenic C. sativa seed oil 
(CSO) that both contained approximately 12% EPA and 9.5% DHA 
(14)
.   Thus, acute consumption 
of this CSO appears to be as effective as FO as a source of EPA and DHA in humans.  However, 
the effectiveness of CSO in raising blood EPA and DHA concentrations when consumed as a 
dietary supplement has not been tested.  To address this, we compared the incorporation of EPA 
and DHA into blood lipids when consumed for 8 weeks as either a commercial FO or CSO in 
healthy adults in a randomised cross-over study.    
       
Material and methods 
Preparation of Camelina sativa oil 
Transgenic C. sativa plants producing a seed oil containing EPA and DHA were generated as 
described
(14)
.  Homozygous T3 generation transgenic C. sativa plants were grown in a controlled 
environment containment glasshouse under long-day conditions (16 h light and 8 h dark), 50–60 % 
relative humidity, with temperature 23°C day /18°C night, and with a light intensity of 400 μmol/m
2
 
per s. Seeds were harvested, threshed, and the oil was then extracted
(14)
. Further processing by 
refining, bleaching and deodorizing was carried out by POS Bio-Sciences (Saskatchewan, Canada). 
 
Human dietary supplementation study 
The study was reviewed and approved by the South Central – Hampshire B Research Ethics 
Committee (REC reference 15/SC/0627).  The trial is registered at ClinicalTrials.gov (identifier: 
NCT03477045). All participants gave written informed consent. 
  The participants were healthy men and women whose characteristics are summarised in 
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to be within normal clinical ranges for blood pressure, to have total cholesterol and 
non-fasting glucose concentrations within accepted ranges, to not habitually consume FO or other 
dietary oil supplements, or not eating more than one oily fish meal per week, to be willing and able 
to adhere to the study protocol, and able to provide written informed consent.  Volunteers were 
excluded if they had a body-mass-index greater than 30 kg/m
2
, clinician diagnosed chronic illness 
or food allergy, were regular user of anti-inflammatory medication or had been prescribed 
medication to control blood lipid concentrations or fat absorption, or to control blood pressure or 
chronic gastrointestinal disease.  Volunteers were also excluded who were pregnant or planning to 
become pregnant during the study period or were participating in another clinical trial.  Because we 
have shown that there were no significant differences between sexes or between ages in acute 
incorporation of EPA and DHA into blood lipids
(14)
, the participants were studied as a single group 
of mixed ages and sexes. 
 The trial had a blinded crossover design.  After health screening by questionnaire and by 
measurement of anthropometric and biochemical markers, participants were randomised to 
consume 450 mg EPA+DHA per day provided either by the CSO or a commercial blended FO 
(Simply Timeless®, Omega-3 FO plus cod liver oil; Seven Seas) in random order for a period of 8 
weeks followed by a washout interval of 6 weeks.  Randomisation was carried out using a random 
number generator (www.random.org).  Participants were instructed not to consume more than one 
fish meal per week and if fish were consumed that it should not be oily.  Compliance was assessed 
verbally on each study visit and there was no evidence of non-compliance.   Participants then 
consumed the other test oil for a further 8 weeks.  The fatty acid compositions of the oils are 
detailed in Table 2.  Blinding was achieved by dispensing the test oils into identical containers that 
were filled and labeled by a researcher who was not a member of the study team.  However, 
blinding was incomplete because the FO retained some residual odor and taste. Participants were 
instructed to dispense the appropriate volume of test oil (CSO, 2.4 ml; FO, 1.6 ml) using an oral 
dosing syringe and to consume this once per day in the morning just before breakfast so that the oil 
would mix with ingested food and also induce an insulinogenic response required to promote 
hydrolysis of dietary lipids in blood.  Compliance was assessed by weighing the individual bottles 
containing the test oils before and at the end of each supplementation period and then comparing 
the difference to the change in weight expected if the correct amount of oil was withdrawn each 
day. 
 Venous blood samples (40 ml) were collected using lithium heparin anticoagulant after 
participants fasted for 12 hours at the start and end of each supplementation period.  The blood 
samples were separated into plasma and cell fractions
(15)
.  Plasma and erythrocytes were stored at -
80
o
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Analysis of the fatty acid composition of blood and erythrocyte lipids 
We have shown that the structures of EPA and DHA – containing TG differ between FO and CSO 
which may, in turn, modify the incorporation of these fatty acids into plasma lipid classes
(16)
.  We, 
therefore, undertook a comprehensive analysis of the incorpration of EPA and DHA into the main 
plasma lipid classes.  The fatty acid composition of plasma TG, phosphatidylcholine (PC), 
cholesteryl esters (CE) and non-esterified fatty acids (NEFA) was determined by gas 
chromatography as described 
(15; 17)
.  Briefly, the internal standards dipentadecanoylPC (100 μg), 
triheptadecanoin (100 μg), heneicosanoic acid (50 μg) and cholesteryl heptadecanoate (100 μg) 
were added to plasma (0.8 ml) and total lipids then extracted with chloroform : methanol (2:1, 
v/v)
(17,18)
.  Individual lipid classes were isolated by solid phase extraction as described previously
(17)
 
on a 100 mg aminopropylsilica column (BondElut; Agilent Technologies, Cheshire, UK)
(19)
.  Fatty 
acid methyl esters (FAME) were prepared by reaction of isolated lipids with methanol containing 
2% (v/v) sulphuric acid at 50 
o
C for 2 hours
(17)
.  FAME were resolved on a BPX-70 fused silica 
capillary column (30 m x 0.25 mm x 25 μm) using an Agilent 6890 gas chromatograph equipped 
with flame ionization detection
(15)
.  Fatty acids were identified by their retention times relative to 
standards (37 FAMES, Sigma-Aldrich, Dorset, UK).  The concentrations of individual FAME were 
determined by comparison of the peak area to that of the internal standard with adjustment for the 
volume of plasma that was extracted. 
 Erythrocytes were extracted with chloroform/methanol 2:1 as described
(20)
.   The fatty acid 
composition of total erythrocyte lipids was determined by gas chromatography using the same 





Measurement of the size and concentration of lipoproteins 
Determination of the concentration and diameter of chylomicrons (CM), VLDL, LDL, IDL and 
HDL particles was carried out using NMR spectroscopy by LipoScience Incorporated as described 
previously
(14)
.  Because the size of VLDL and CM particles can overlap, the size distributions and 
concentrations of these particles are reported as a combined VLDL+CM fraction which in fasting 
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Measurement of plasma total triacylglycerol and glucose concentrations 
Plasma TG, NEFA and glucose concentrations were measured using a Konelab 20 autoanalyser 
(Labmedics Limited, Manchester, UK) as described
(21)
. Reagents were from Microgenics GmbH 
(Hemel Hempstead, UK) and Alpha Laboratories (Eastleigh, Hampshire, UK). 
 
Statistical methods  
There are currently no other dietary supplementation studies involving the CSO on which to base a 
calculation of sample size.  Consequently, we used the findings of our prevous study
(22) 
to esimate 
the statistical power of this exploratory study.  Thirty-one participants were estimated, using online 
calculators at www.dssresearch.com, to provide 85 % power for detecting a 4 % difference in the 
primary endpoint, DHA concentration in plasma PC between test oils, at α = 5 % in paired two-
tailed analysis.  Data were analysed using the SPSS statistical analysis programme (IBM Corp. 
(released 2017) IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY).  Any effects of the 
order in which the oils were consumed were tested by students paired t test of the absolute changes 
in concentration during each period of supplementation
(23)
.  If no order effects were found, data 
were pooled for each type of oil irrespective of the order in which the oil was consumed and the 
effects of the test oils on EPA and DHA concentrations were analysed using Student’s paired t 
test
(23)
.  Data which were not normally distributed were analysed using the Mann-Whitney U test. 
Adjustment for multiple testing was carried out for data sets that showed a statistically significant 




Participant recruitment, tolerance of the trial and compliance 
One hundred and forty individuals enquired about the study, of which 69 did not complete the 
screening questionnaire for undisclosed reasons (Fig. 1). Seventy-one of the remaining individuals 
were assessed for eligibility against study inclusion criteria.  Thirty-nine of these were found to be 
ineligible or decided not to participate.  The remaining thirty-two volunteers gave written informed 
consent to take part in the study, and were randomised to one of the two test oils.  One participant 
withdrew after commencing the supplementation due to perceived unpalatability of the FO 
supplement. Thirty-one participants completed both supplementation periods.  The median (range) 
compliance to the supplementation protocol was FO 97 (71 – 103) % and CSO 99 (82 – 113) %.  
There was no statistically significant difference in compliance (p = 0.2) between test oils by the 
Wilcoxon Matched-Pairs Signed Rank Test.  Some participants who exceeded 100% compliance 
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highest compliance value consumed 113% of the intended amount which is equivalent to an extra 
38 mg/day EPA and 30 mg/day DHA over the 8 weeks supplementation period. There was no 
significant effect of the order in which test oils were consumed on the incorporation of EPA or 
DHA into plasma lipids (all P > 0.05) or on any of the other outcomes that were measured.  
Therefore, data from each arm of the crossover study were pooled according to the test oil that was 
consumed.  There were no significant differences between male or female participants in the change 
from baseline EPA or DHA concentrations after consuming the test oils (all P > 0.05).    
 One participant withdrew from this study.  This was because they found the FO supplement 
unpalatable (Fig. 1). All other participants tolerated supplements well. Three adverse events were 
reported during intervention, including one case of “fishy burps” when consuming FO, one case of 
exacerbation of pre-existing dermatitis, and one case of stomach irritation that did not appear to be 
due to either of the test oils.   
 
The effect of dietary supplementation with FO or CSO on EPA and DHA concentrations in plasma 
lipids 
 Consuming either FO or CSO for eight weeks significantly increased plasma PC EPA 
concentration by 49% and 79%, respectively, compared to baseline (Table 3).  Consuming FO or 
CSO for eight weeks increased EPA concentration in plasma TG by 50% and 98%, respectively 
(Table 3).  Consuming CSO for eight weeks significantly increased EPA concentration (29%) in 
plasma non-esterified fatty acids (NEFA) (Table 3), while the increase following consumption of 
FO (49%) failed to reach statistical significance. Consuming FO or CSO for eight weeks 
significantly increased EPA concentration by 52% and 49%, respectively, in plasma cholesteryl 
esters (CE).  There was no statically significant difference between test oils in the increment in EPA 
concentration in either plasma NEFA or CE.   
 Consuming either FO or CSO for eight weeks significantly increased DHA concentration in 
plasma PC by 49% and 74%, respectively, and in plasma TG by 41% and 72%, respectively (Table 
3).  Consuming FO or CSO increased DHA concentration in plasma NEFA by 11% and 22%, 
respectively, although this change did not reach statistical significance.  Consuming FO or CSO 
increased plasma CE DHA concentration by 29% and 27%, respectively, compared to baseline, 
although this only reached statistical significance after consuming FO (Table 3).  There were no 
significant differences between test oils in the magnitude of change in DHA concentration from 
baseline in any of the plasma lipid classes that were measured (Table 3).     
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There were no significant effects (P > 0.05) of the order in which the test oils were consumed on 
fasting plasma glucose, or total TG, NEFA and CE.  Consuming FO induced a statistically 
significant decrease in plasma glucose (4%) and TG (20%) concentrations (Table 4).  Consuming 
CSO did not alter the concentrations of plasma glucose, TG, CE, or NEFA.  There was no 
statistically significant difference between test oils in any change in plasma glucose or lipid 
concentrations.  
 
The effect of dietary supplementation with FO or CSO on lipoprotein size and concentration  
Dietary supplementation with either CSO or FO decreased VLDL+CM TG concentration, although 
this only reached statistical significance when participants consumed FO (Table 5).  There were no 
other significant changes in lipoprotein concentration or size between the start and end of the 
supplementation period.  There were no significant differences between test oils in the difference in 
lipoprotein concentrations and size between the start and end of the intervention periods (Table 5). 
 
The effect of dietary supplementation with FO or CSO on EPA and DHA concentrations in 
erythrocyte lipids 
Dietary supplementation with either FO or CSO significantly increased the proportion of EPA in 
erythrocytes by 27% and 40%, respectively, which did not differ significantly between test oils 
(Table 6).  There was no significant change in the proportion of DHA following supplementation 
with FO (Table 6).  Supplementation with CSO induced a small (6%) but statistically significant 
increase on the proportion of DHA in erythrocytes.  The magnitude of the change in the proportion 
of DHA did not differ significantly between test oils. 
 Supplementation with either FO or CSO induced a modest, statistically significant increase 
in the Omega-3 Index, 8% and 12%, respectively (Table 6).  There was no significant difference 
between test oils in the magnitude of the change in the Omega-3 Index.  
  
Discussion  
The findings of this study show that consumption of EPA and DHA from CSO was as effective as 
FO in increasing the concentrations of EPA and DHA in plasma lipids and in erythrocytes. 
 The participants appeared to tolerate the test oils.  The one participant who withdraw from 
the study did so because they found the FO unpalatable.  This is consistent with unpalatability being 
a major factor in the reluctance of the UK population to consume oily fish
(8; 9)
 and so supports the 
suggestion that consumption of CSO is a potential means to overcome unpalatability as a barrier to 
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 Consuming either CSO or FO increased the concentrations of EPA and DHA in the four 
plasma lipid classes that were measured.  Thus relatively short term supplementation with the 
amount of EPA+DHA recommended by the UK Government
(7)
 is effective in raising blood 
concentrations of these PUFA.  In the fasting state, plasma PC and TG reflect primarily hepatic 
synthesis and are carried by liver-derived lipoproteins, while the NEFA pool mainly reflects 
hydrolysis of TG in adipose tissue
(24)
.  Therefore, these findings suggest that consumption of CSO 
can induce comparable enrichment of EPA and DHA in hepatic and adipose tissue pools.  The rank 
order of EPA incorporation in plasma lipids was PC ≡ CE > TG > NEFA, while the rank order of 
the increment in DHA concentrations was PC > TG ≡ NEFA irrespective the test oil.  Other studies 
have also reported differential incorporation of EPA and DHA into plasma lipid classes.  For 
example, following dietary supplementation of men with FO, EPA was enriched in both plasma 
phospholipids and TG, with a greater incorporation into phospholipids, but DHA was only enriched 
in TG
(25)
.   EPA has also been shown to be incorporated preferentially into phospholipids and CE, 
while DHA was incorporated predominately into phospholipid and TG
(26)
.  A study that 
investigated the incorporation of EPA and DHA consumed in different lipid structures into plasma 
lipids found that the increase in EPA and DHA was PC > TG > NEFA in men and women
(15)
.  It is 
unclear why different studies report differing distributions of EPA and DHA between plasma lipid 
classes, although this does not appear to be influenced by the dietary source or the relative amounts 
of EPA and DHA, the structure of the ingested lipid, or the sex of the participants.  However, such 
differences may have implications for understanding the metabolism of EPA and DHA, and for the 
use of plasma lipids as biomarkers of EPA and DHA status. 
 There were no significant differences between test oils in the increments of EPA and DHA 
concentration in blood lipids or in erythrocytes after 8 weeks supplementation with 450 mg / day 
EPA+DHA provided as FO or CSO.  This is in agreement with the pattern of postprandial 
incorporation of EPA and DHA into plasma lipids when consumed as FO or CSO
(14)
 and consistent 
with the view that CSO is as effective as FO in raising EPA and DHA concentrations when 
consumed in the amount recommended by the UK Government.  Thus, CSO is a potential 
alternative source of EPA and DHA for inclusion in the human diet.  Moreover, CSO is potentially 
able to overcome the current barriers to achieving the level of EPA+DHA intake, in particular the 
perceived unpalatability of oily fish and dietary choices that exclude animal derived foods. 
 The present findings indicate that consumption of CSO may confer the health benefits that 
have been attributed to FO, although the study was not designed specifically to test health-related 
outcomes because participation was restricted to healthy, normotriglycerideamic participants, and 
was probably underpowered to detected health related outcomes, and the level of EPA+DHA 
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including reduction in blood TG concentration which typically requires intakes of greater than 2 g 
EPA+DHA/day
(27)
.  Nevertheless, the decrease in plasma TG and VLDL+CM TG concentrations 
induced by consuming either FO (-10.4 mmol/l) or CSO (-8.0 mmol), although the latter failed to 
reach statistical significance, was comparable to the reduction in plasma TG induced in 
normotriglyceridaemic men who consumed purified 3.6 g/day EPA or DHA
(28)
.     
 The proportions of EPA and DHA in erythrocytes appear to reflect longer term intakes of 
these PUFA compared to more rapidly changing plasma lipids
(29; 30)
, although the strength of this 
association may be modified by acyl exchange between erythrocyte and plasma lipids
(31)
, and by 
acyl remodelling and turnover which can be modified by dietary factors such as alcohol intake
(32)
.  
Nevertheless, the proportion of EPA+DHA in erythrocytes has been demonstrated to be a robust 
predictive biomarker of cardiovascular disease risk
(5)
.  The present findings show that there was no 
significant difference between test oils in the increase in the proportions of EPA and DHA in 
erythrocytes nor in the modest increase in the omega-3 index.   Together, the changes in plasma and 
VLDL+CM TG, and in the omega-3 index suggest that consumption of CSO is potentially as 
effective as an equivalent intake of EPA+DHA provided as FO in ameliorating this risk factor and 
biomarker of cardiovascular disease risk.   Thus, it is reasonable to speculate that higher intakes of 
CSO over a longer period could induce clinically relevant changes in cardiovascular disease risk. 
 The main limitation of the study is that the amount of EPA and DHA consumed per day was 
too low and the duration of the intervention too short to test fully for beneficial effects of CSO in 
lowering plasma TG concentration or to raise the Omega-3 index.  Moreover, there were too few 
participants to test for effects of age or adiposity on the incorporation of EPA and DHA into blood 
and cell lipids.  Finally, there may be merit in a larger trial that includes different population 
subgroups such as patients with dyslipidaemia or inflammatory disease.         
  In conclusion, the present findings, together with those from a study of acute intake of 
CSO
(14)
, show that this oil from a transgenic plant is as effective as FO when consumed at an 
amount with equivalent EPA+DHA content in increasing blood and erythrocyte contents.  
Furthermore, the findings suggest that CSO may be able to confer health benefits that have been 
attributed to FO.  Importantly, the transgenic oil was well tolerated.  Thus overall CSO is 
potentially an effective  source of EPA and DHA for human consumption.  Moreover, it does not 
incur the current challenges to the UK population achieving recommended intakes of these PUFA, 
namely concerns about palatability and contamination with environmental pollutants, and is 
consistent with dietary choices that exclude meat, while being potentially scalable without 
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Table 1. Characteristics of participants at enrollment 
 
 Mean or median SEM or range 
Proportion of females (%) 56  
Age (years) 53† 20 – 74 
Height (m) 1.72 0.02 
Weight (kg) 72.4 2.5 
Body-mass-index (kg/m
2
) 24.5 0.5 
Systolic blood pressure (mmHg) 117.7 23 
Diastolic blood pressure (mmHg) 69.1 1.5 
Fasting plasma glucose (mmol/l) 5.1 0.1 
Total plasma cholesterol (mmol/l) 4.9 0.2 
Total plasma TG (mmol/l) 0.8† 0.2 – 2.9 
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Table 2.  Fatty acid compositions of the test oils 
 
 Proportion of total fatty acids (% total fatty acids) 
Fatty acid CSO FO 
14:0 0.1 6.5 
16:0 6.6 15.0 
16:1n-7 0.2 9.0 
18:0 5.5 2.9 
18:1n-9 5.9 14.5 
18:1n-7 1.6 4.1 
18:2n-6 19.9 1.6 
18:3n-6 3.1 0.2 
18:3n-3 13.6 1.1 
20:0 2.9 0.2 
20:1n-9 6.1 6.6 
20:2n-6 0.9 0.3 
20:3n-6 0.9 0.2 
20:4n-6 2.9 1.0 
20:4n-3 2.8 6.2 
EPA 10.8 16.0 
24:0 1.0 0.1 
22:5n-3 6.6 1.9 
DHA 8.6 12.9 
EPA+DHA 19.4 28.9 
Total SFA 16.1 24.7 
Total MUFA 13.8 34.1 
Total n-6 PUFA 27.6 3.2 
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Table 3.  Effect of dietary supplementation with FO or CSO on eicosapentaenoic acid and docosahexaenoic acid concentrations in plasma lipids 
  
 Concentration (μmol/l) Change from baseline Δ FO versus Δ CSO 
 Start End Difference P P 
 Mean  SEM Mean  SEM Mean  SEM   
PC Eicosapentaenoic acid   
     FO 29.4 2.9 43.7 4.8 14.3 4.0 0.001 0.3 
     CSO 28.5 3.5 49.6 6.8 21.1 5.2 <0.0001  
TG         
     FO 5.0 0.7 7.5 0.9 2.5 0.8 0.003 0.3 
     CSO 4.9 0.6 9.7 2.0 4.8 1.8 0.01  
NEFA         
     FO 0.7 0.1 0.9 0.1 0.2 0.1 0.07 0.5 
     CSO 0.7 0.1 1.0 0.1 0.3 0.1 0.006  
CE         
     FO 27.8  3.5 42.3 5.9 14.4 4.3 0.002 0.3 
     CSO 27.2 3.8 48.6 7.0 21.4 4.9 0.02  
PC Docosahexaenoic acid   
     FO 80.2 5.6 96.2 8.9 15.9 4.8 0.003 0.9 
     CSO 82.0 8.5 98.6 9.1 16.6 5.3 0.004  
TG         
     FO 7.3 1.0 10.3 1.1 3.0 1.0 0.005 0.4 
     CSO 8.2 1.3 14.1 3.8 5.9 3.4 0.09  
NEFA         
     FO 2.7 0.5 3.0 0.6 0.3 0.5 0.5 0.8 
     CSO 2.3 0.3 2.8 0.3 0.5 0.3 0.2  
CE         
     FO 11.3 1.0 14.6 1.7 3.3 1.0 0.001 0.9 
     CSO 12.6 1.4 15.7 2.0 3.1 1.3 0.2  
Values are mean ± SEM (n 31).  All data approximated a normal distribution.  The mean concentrations of EPA and DHA at the start and end of the 
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Table 4.  The effect of dietary supplementation with FO or CSO on plasma glucose and lipid concentrations 
  
 Concentration (mmol/l) Start versus 
end 
Δ FO versus Δ 
CSO 
 Start End Difference P P 
 Mean SEM Mean SEM Mean SEM   
   Triacylglycerol   
FO 1.0 0.1 0.8 0.1 -0.2 0.1 0.02 0.4 
CSO 0.9 0.1 0.8 0.1 -0.1      0.1 0.1  
 Cholesteryl esters   
FO 2.9 0.2 3.0 0.3 0.2 0.1 0.2 0.7 
CSO 3.1 0.3 3.2 0.3 0.1 0.2 0.4  
 Non-esterified fatty acids   
FO 0.3 0.1 3.0 0.1 0.1 0.1 0.3 0.4 
CSO 0.1 0.1 0.1 0.1 0.1 0.1 0.9  
Glucose   
FO 4.8 0.1 4.6 0.1 -0.2 0.1 0.04 0.9 
CSO 4.8 0.1 4.8 0.1 0.1 0.1 0.5  
 
Values are mean ± SEM n 31 and all data approximated a normal distribution. The mean concentrations of EPA and DHA at the start and end of the 
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Table 5.  The effect of dietary supplementation with FO or CSO  on lipoprotein concentration and size 
 Lipoprotein concentration and size Student’s t-test (P) 
  FO  CSO Start versus 
end 
ΔFO versus Δ 
CSO 
 Start End Difference Start End Difference FO CSO  
 Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM    
 Concentration (nmol/l)    
Total VLDL+CM 40.9 2.7 39.0 2.9 -1.9 2.6 45.9 3.3 39.5 3.8 -6.3 4.0 0.5 0.1 0.2 
Total LDL 965 60 946 57 -19 44 918 64 997 62 79 41 0.7 0.1 0.7 
Total IDL 151 14 147 16 -4 1.8 169 19 155 22 -14 25 0.8 0.6 0.1 
Total HDL(x10
-3
) 32 31 31 1 -1 1 31.8 1 31.7 1 -0.1 0.9 0.2 0.9 0.4 
VLDL+CM TG 70.4 5.5 60.0 3.9 -10.4 4.2 68.3 1.8 60.2 5.1 -8.0 4.3 0.02 0.07 0.7 
HDL-C 56.9 3.3 55.9 2.9 -0.9 2.2 56.7 2.8 58.4 2.7 1.6 1.8 0.7 0.4 0.4 
 Size (nm)    
Total VLDL+CM 51.0 1.4 49.8 1.0 -2.3 1.4 49.1 1.3 49.1 1.1 0.1 1.2 0.4 0.9 0.8 
Total LDL 20.8 0.1 20.9 0.1 0.2 0.1 20.7 0.1 20.9 0.1 0.1 0.1 0.1 0.2 0.8 
Total HDL 9.7 0.1 9.7 0.1 0.1 0.1 9.7 0.1 9.7 0.1 0.03 0.06 0.2 0.7 0.9 
 
Values are mean ± SEM (n  31).  All data approximated a normal distribution.  The change in mean particle concentration and size at the start and end 
of the trial, and the effect of the type of oil on the mean change in lipoprotein concentrations from baseline were compared using Student’s paired t 
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Table 6.  Effect of dietary supplementation with FO or CSO on the proportions of eicosapentaenoic acid and docosahexaenoic acid in erythrocyte total 
lipids 
  
 Proportion (% total fatty acids) Change from baseline Δ FO versus Δ CSO
3
 
 Start End Difference t- test 
 Mean SEM Mean SEM Mean SEM P P 
 Eicosapentaenoic acid 
FO 1.1 0.1 0.3 0.1 0.3 0.1 < 0.0001 0.3 
CSO 1.0 0.1 0.4 0.1 0.4 0.1 <0.0001  
     
 Docosahexaenoic acid 
FO 5.1 0.2 5.3 0.2 0.2 0.2 0.2 0.1 
CSO 5.0 0.2 5.3 0.2 0.3 0.1 0.03  
  
   Omega-3 index 
FO 6.2 0.2 6.7 0.2 0.5 0.2 0.02 0.2 
CSO 6.0 0.3 6.8 0.2 0.7 0.2 < 0.0001  
 
Values are mean ± SEM (n  31).  All data approximated a normal distribution.  The change in mean proportions of EPA and DHA, and Omega-3 index 
between the start and end of the trial, and the effect of the type of oil on the mean change in proportions of EPA, DHA and the Omega-3 index were 
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